Replies to post #241028 on Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

I am leaning towards Ffroldo (had to get that out of my system) on this one - around $2M left to pay. It is likely that the $4M commitment does not reflect the latest payment made to CRO (~ $2M from Aspire deal). For one thing I have hard time accepting cost of statistical analysis alone being in multiple millions. Of course, if IPIX has been underpaying for some time now, the sum might be for trial analysis plus what was otherwise owed. A complicated mess. And...

We are witnessing why CROs so desperately wanted to get rid of fixed price clinical trial contracts. They were the bagholders then.

BTW: If IPIX and CRO were in arbitration would we know about that? Maybe Loanranger can enlighten me on all this. Meanwhile ... I really need some fresh air and inspiring sceneries - I go go biking now.

[proBIO]

I believe that IPIX made sound decisions using this CRO and decided to use a fixed-pricing model — the right CRO and the right pricing model. Even though financial guys like Leo prefer the variable-pricing model, the right decision was to use a fixed-pricing model. Don’t worry IPIX longs, we will get through this little speed bump and those who purchased IPIX stock at these low levels will rollin’ in the $$$ as soon as the first week of October. Remember that Rothschild made a ton of $$$ upon buying when “there’s blood in the streets.”

Go IPIX!!!

https://www.clinicalleader.com/doc/is-your-cro-charging-you-the-right-price-0001#

https://www.investopedia.com/articles/financial-theory/08/contrarian-investing.asp

[Hazelhurst]

Supposedly they went with the “best” CRO for the P trial. Apparently the best isn’t cheap.